RxDoctor Payments Data

John McDonough, DO

Internal Medicine · Dickson, TNNPI 1336777986

Payments from drug & device makers

$1,060in general payments, 2019–2025

Across 56 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$174
  • AstraZeneca$173
  • Pfizer$133
  • Amgen$77
  • Bayer$70
  • Boehringer Ingelheim$52
  • plus $380 from 14 others

What the payments were for

  • Food & beverage$1,060100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,060 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$195,394
Medicare patients
420
Services billed
7,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$104,836
FarxigaDapagliflozin Propanediol106$101,635
Trelegy ElliptaFluticasone/Umeclidin/Vilanter115$88,684
EliquisApixaban74$67,300
MounjaroTirzepatide53$58,689
JardianceEmpagliflozin53$58,289
XareltoRivaroxaban32$32,292
JanuviaSitagliptin Phosphate13$22,496
Soliqua 100-33Insulin Glargine/Lixisenatide17$21,274
GemtesaVibegron19$18,860
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$17,855
Breo ElliptaFluticasone/Vilanterol21$10,156
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$6,126
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$5,604
Rosuvastatin Calcium331$4,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$173$119,489129 claims
Novo NordiskOzempic$174$104,83681 claims
GSKTrelegy Ellipta, Breo Ellipta$44$98,839136 claims
PfizerEliquis$133$67,30074 claims
Lilly USA, LLCMounjaro$43$58,68953 claims
Boehringer IngelheimJardiance$52$58,28953 claims
AbbVieSynthroid$35$1,38128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Dickson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →